Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia 将出席 2024 年加拿大皇家银行资本市场全球医疗保健会议
May 7, 2024 • 6:00 am EDT Download as PDF
2024 年 5 月 7 日 • 美国东部时间上午 6:00 以 PDF 格式下载
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.
马里兰州罗克维尔和艾伯塔省埃德蒙顿--（美国商业资讯）--奥里尼亚制药公司（纳斯达克股票代码：AUPH）（Aurinia或公司）今天宣布，它将参加2024年5月14日至15日在纽约举行的2024年加拿大皇家银行资本市场全球医疗保健会议。
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia's website, which can be found here.
奥里尼亚管理层将与投资者举行一对一的会议，并将于美国东部时间5月15日星期三上午10点至10点25分参加炉边谈话。该会议的网络直播将在Aurinia网站的 “投资者” 栏目上播出，该栏目可以找到 这里。
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company's head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
关于 Aurinia
Aurinia Pharmaceuticals是一家完全整合的生物制药公司，专注于为医疗需求未得到满足的自身免疫性疾病患者提供疗法。2021 年 1 月，公司推出了 LUPKYNIS （voclosporin），美国食品药品管理局批准的第一种口服疗法，专门用于治疗活动性狼疮肾炎的成年患者。该公司的总部位于艾伯塔省埃德蒙顿，其美国商业办公室位于马里兰州的罗克维尔。该公司将开发工作重点放在全球各地。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507143335/en/
在 businesswire.com 上查看源版本： https://www.businesswire.com/news/home/20240507143335/en/
Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com
媒体和投资者查询：
安德里亚克里斯托弗
企业传播和投资者关系，Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
资料来源：Aurinia Pharmicals Inc.
Released May 7, 2024
2024 年 5 月 7 日发布